Arrowhead Pharmaceuticals (NASDAQ:ARWR) posted its earnings results on Monday. The biotechnology company reported $0.11 EPS for the quarter, missing the consensus estimate of $0.14 by ($0.03), Fidelity Earnings reports. Arrowhead Pharmaceuticals had a return on equity of 26.27% and a net margin of 33.28%.
Shares of NASDAQ ARWR opened at $56.99 on Tuesday. The company has a market capitalization of $4.66 billion, a P/E ratio of -87.68 and a beta of 1.68. Arrowhead Pharmaceuticals has a 52-week low of $10.41 and a 52-week high of $59.72. The company’s 50 day moving average price is $40.43 and its 200-day moving average price is $30.84.
In other news, Director Michael S. Perry sold 100,000 shares of the business’s stock in a transaction that occurred on Monday, September 9th. The shares were sold at an average price of $28.90, for a total value of $2,890,000.00. Following the transaction, the director now owns 121,000 shares in the company, valued at approximately $3,496,900. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Michael S. Perry sold 85,000 shares of the business’s stock in a transaction that occurred on Wednesday, September 11th. The stock was sold at an average price of $30.00, for a total transaction of $2,550,000.00. Following the completion of the transaction, the director now owns 121,000 shares in the company, valued at approximately $3,630,000. The disclosure for this sale can be found here. Insiders sold a total of 350,104 shares of company stock worth $10,783,025 in the last 90 days. Corporate insiders own 4.80% of the company’s stock.
About Arrowhead Pharmaceuticals
Arrowhead Pharmaceuticals, Inc develops medicines for the treatment of intractable diseases in the United States. The company's pipeline include ARO-AAT, a RNA interference (RNAi) therapeutic candidate for the treatment of liver diseases associated with alpha-1 antitrypsin deficiency; ARO-APOC3 to treat hypertriglyceridemia; ARO-ANG3 to reduce production of angiopoietin-like protein 3; ARO-ENaC to reduce production of the epithelial sodium channel alpha subunit in the airways of the lung; and ARO-HIF2 for the treatment of clear cell renal cell carcinoma.
Featured Story: Market Capitalization – What it Means for Investors
Receive News & Ratings for Arrowhead Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arrowhead Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.